191eTiP The Syrian TELE-TAT trial: A pragmatic, randomized study of tele-oncology for proactive adverse event management in patients receiving oral targeted therapies in a conflict zone
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
In conflict-affected, resource-limited settings such as Syria, the safe delivery of oral targeted anticancer therapies (OTATs), including tyrosine kinase inhibitors (TKIs) such as imatinib and ibrutinib, is severely compromised. Geographic barriers, security risks, and economic constraints make standard in-clinic monitoring for adverse events (AEs) largely inaccessible, leading to unmanaged toxicities, high rates of treatment interruption, and suboptimal outcomes. Proactive, low-technology tele-oncology offers a pragmatic solution to this critical gap in supportive care, but its efficacy in such extreme environments remains unproven.
Fields of Study & Subjects
Telemedicine and Telehealth Implementation
Cancer survivorship and care
COVID-19 and healthcare impacts
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106198–106198
- Publication date
- 1 April 2026
- Language
- EN